 Tozerakimab is a new type of therapeutic drug that has been developed to treat inflammatory diseases. It works by blocking two different types of signals released by interleukin, 33, Illinois, 33. The first signal is called Illinois, 33 red, which is released when there is damage to tissues. This signal activates a protein called SD2, which then triggers inflammation. Tozerakimab also blocks another signal called Illinois, 33 ox, which is produced when Illinois, 33 is oxidized. Oxidization occurs naturally when it is exposed to air or light. This signal activates a protein called RAGE, which then leads to more inflammation. By blocking both these signals, Tozerakimab is able to reduce inflammation and improve healing. This article was authored by Elizabeth England, D. Gareth Reese, Ian Christopher Scott and others.